Resistance issues in treating chronic hepatitis B

Future Microbiology

Volumn 3, Issue 5, 2008, Pages 525-538

  Papatheodoridis, George V ^a   Deutsch, Melanie ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adefovir; Entecavir; HBV DNA; Hepatitis; Lamivudine; Resistance; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CHRONIC DRUG ADMINISTRATION; CHRONIC HEPATITIS; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HUMAN; MULTIDRUG RESISTANCE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETREATMENT; REVERSE TRANSCRIPTION; REVIEW; TREATMENT DURATION; VIRUS MUTATION; VIRUS REPLICATION; DRUG EFFECT; HEPATITIS B VIRUS;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 55449100302     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.5.525     Document Type: Review

References (100)

1. Lee WM: Hepatitis B virus infection. N. Engl. J. Med. 337, 1733-1745 (1997).
2. Maddrey WC: Hepatitis B: an important public health issue. J. Med. Virol. 61, 362-366 (2000).
3. Hadziyannis SJ, Papatheodoridis GV: Hepatitis B e antigen negative chronic hepatitis B - natural history and treatment. Semin. Liver Dis. 26, 130-141 (2006).
4. Kane M: Global programme for control of hepatitis B infection. Vaccine 13, S47-S49 (1995).
5. Lai CL, Chien RN, Leung NW et al.: one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998).
6. Tassopoulos NC, Volpes R, Pastore G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29, 889-896 (1999).
7. Marcellin P, Chang TT, Lim SG et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808-816 (2003).
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003).
9. Chang TT, Gish RG, de Man R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006).
10. Lai CL, Shouval D, Lok AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006).
11. Lai CL, Gane E, Liaw YF et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007).
12. Heathcote J, Gane E, de Man R et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology 46(Suppl. 1), 861A (2007).
13. Marcellin P, Buti M, Krastev Z et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. Hepatology 46(Suppl. 1), 290A (2007).
14. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ: Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect. Dis. 8, 167-178 (2008).
15. Hadziyannis SJ, Papatheodoridis GV: Emerging treatments in chronic hepatitis B. Expert Opin. Emerg. Drugs 9, 207-221 (2004).
16. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of α-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119, 312-323 (1993).
17. Niederau C, Heintges T, Lange S et al.: Long-term follow-up of HBeAg-positive patients treated with interferon-α for chronic hepatitis B. N. Engl. J. Med. 334, 1422-1427 (1996).
18. Manesis EK, Hadziyannis SJ: Interferon- α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121, 101-109 (2001).
19. Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 34, 306-313 (2001).
20. Lau GKK, Piratvisuth T, Luo KX et al.: Peginterferon α-2a. lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005).
21. Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365, 123-129 (2005).
22. Marcellin P, Lau GK, Bonino F et al.: Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004).
23. Benhamou Y, Dohin E, Lunel-Fabiani F et al.: Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345, 396-397 (1995).
24. Jarvis B, Faulds D: Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58, 101-141 (1999).
25. Papatheodoridis GV, Dimou E, Papadimitropoulos V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. 97. 1618-1628 (2002).
26. Zoulim F: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral. Res. 64, 1-15 (2004).
27. Shaw T, Bartholomeusz A, Locarnini S: HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44, 593-606 (2006).
28. Radiwell G: Mutational analysis of the hepatitis B virus P gene product: domain structure and RNAse H activity. J. Virol. 64, 613-620 (1990).
29. Toh H, Hayashida H, Miyata T: Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 305, 827-829 (1983).
30. Johnson MS, McClure MA, Feng DF et al.: Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc. Natl Acad. Sci. USA 83, 7648-7652 (1986).
31. Doo E, Liang TJ: Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 120, 1000-1008 (2001).
32. Drake JW: Rates of spontaneous mutation among RNA viruses. Proc. Natl Acad. Sci. USA 90, 4171-4175 (1993).
33. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H: Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93, 4398-4402 (1996).
34. Girones R, Miller RH: Mutation rate of the hepadnavirus genome. Virology 170, 595-597 (1989).
35. Locarnini S, Hatzakis A, Heathcote J et al.: Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 9, 679-693 (2004).
36. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-717 (1996).
37. Lok ASF, McMahon BJ: Chronic hepatitis B. Hepatology 45, 507-539 (2007).
38. Papatheodoridis GV, Hadziyannis SJ: Current management of chronic hepatitis B. Aliment Pharmacol. Ther. 19, 25-37 (2004).
39. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36, 219-226 (2002).
40. Di Marco V, Marzano A, Lampertico P et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40, 883-891 (2004).
41. Liaw Y-F, Leung NWY, Chang T-T et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172-180 (2000).
42. Lok AS, Lai CL, Leung N et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722 (2003).
43. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34, 785-791 (2001).
44. Manolakopoulos S, Bethanis S, Elefsiniotis J et al.: Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol. Ther. 23, 787-795 (2006).
45. Van Bommel F, Brodzinski A, Mihm U et al.: Long-term treatment with lamivudine up to ten years: predictive value of host and virus related factors for the development of HBV resistance. J. Hepatol. 48(Suppl. 2), S264-S265 (2008).
46. Yuen MF, Seto WK, Chow DH et al.: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 12, 1295-1303 (2007).
47. Hunt CM, McGill JM, Allen ML, Condreay LD: Clinical relevance of hepatitis B virus mutations. Hepatology 31, 1037-1044 (2000).
48. Allen MI, Deslauriers M, Andrews CW et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27, 1670-1677 (1998).
49. Bartholomeusz A, Locarnini S: Hepatitis B virus mutations associated with antiviral therapy. J. Med. Virol.. 78(Suppl. 1). S52-S55 (2006).
50. Dienstag JL, Goldin RD, Heathcote EJ et al.: Histologic outcome during long-term lamivudine therapy. Gastroenterology 124, 105-117 (2003).
51. Papatheodoridis GV, Dimou E, Dimakopoulos K et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42, 121-129 (2005).
52. Si Ahmed SN, Tavan D, Pichoud C et al.: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32, 1078-1088 (2000).
53. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30, 567-572 (1999).
54. Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin. Liver Dis. 26, 162-170 (2006).
55. Keeffe EB, Dieterich DT, Han S-HB et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 4. 936-962 (2006).
56. Hadziyannis SJ, Papatheodoridis GV: Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev. Anti-infect. Ther. 2, 475-483 (2004).
57. Cundy KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127-143 (1999).
58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
59. Lampertico P, Vigano P, Manenti E, Iavarone M, Lunghi G, Colombo M: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42, 1414-1419 (2005).
60. Yeon JE, Yoo W, Hong SP et al.: Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55, 1488-1495 (2006).
61. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir tehrapy in lamivudine resistant HBeAg-negative chronic hepatitis B. Hepatology 45, 307-313 (2007).
62. Angus P, Vaughan R, Xiong S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125, 292-297 (2003).
63. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41, 1444-1448 (1997).
64. Robinson DM, Scott LJ, Plosker GL: Entecavir: a review of its use in chronic hepatitis B. Drugs 66, 1605-1622 (2006).
65. Colonno RJ, Rose RE, Pokornowski K et al.: Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J. Hepatol 46(Supp. 1), S294 (2007).
66. Tenney D, Pokorowski KA, Rose RE et al.: Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. APASL Abstr.: PL02 (2008).
67. Tenney DJ, Levine SM, Rose RE et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48, 3498-3507 (2004).
68. Keam SJ: Telbivudine. Drugs 67, 1917-1929 (2007).
69. Lai C-L, Leung N, Teo E-K et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129, 528-536 (2005).
70. Lai C-L, Gane E, Hsu C-W et al.: Two-years results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology 44(Suppl. 1), 222A (2006).
71. Di Bisceglie A, Lai C-L, Gane E et al.: Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 44(Suppl. 1), 230A-231A (2006).
72. Kumar A: Tenofovir disoproxil fumarate. Drugs 63, 1609-1610 (2003).
73. Locarnini S, Mason WS: Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44, 422-431 (2006).
74. Heathcote J, George J, Gordon S et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 103). J. Hepatol. 48(Suppl. 2), S32 (2008).
75. Marcellin P, Jacobson I, Habersetzer F et al.: Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102). J. Hepatol. 48(Suppl. 2), S26 (2008).
76. Van Bommel F, de Man R, Stein K et al.: A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J. Hepatol. 48(Suppl. 2), S32 (2008).
77. Sheldon J, Camino N, Rodes B et al.: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. 10, 727-734 (2005).
78. Delaney WE, Ray AS, Yang H et al.: Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 50, 2471-2477 (2006).
79. Zoulim F: Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir. Chem. Chemother. 15, 299-305 (2004).
80. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F: Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131, 1253-1261 (2006).
81. Pawlotsky JM, Dusheiko G, Hatzakis A et al.: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134, 405-415 (2008).
82. Peters MG, Hann HH, Martin P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126, 91-101 (2004).
83. Chang TT, Gish RG, Hadziyannis SJ et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129, 1198-1209 (2005).
84. Lau DTY, Khokhar MF, Doo E et al.: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32, 828-834 (2000).
85. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV: Cross-resistance testing of next-generation nucleosite and nucletide analogues against lamivudine-resistant HBV. Antivir. Ther. 10, 625-633 (2005).
86. Sherman M, Yurdaydin C, Sollano J et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130, 2039-2049 (2006).
87. Van Bommel F, Wunsche T, Mauss S et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40, 1421-1425 (2004).
88. Van Bommel F, Zollner B, Sarrazin C et al.: Tenofovir for patients with lamivudine resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44, 318-325 (2006).
89. Fung SK, Chae HB, Fontana RJ et al.: Virologic response and resistance to adefovir in patients with chronic-hepatitis B. J. Hepatol. 44, 283-290 (2006).
90. Shaw T, Bowden S, Locarnini S: Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology 126, 343-347 (2004).
91. Lampertico P, Vigano P, Manenti E, Iavarone M, Lunghi G, Colombo M: Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Hepatology 42(Suppl. 1), 582A-583A (2005).
92. Berg T, Moller B, Trinh H et al.: Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). J. Hepatol. 48(Suppl. 2), S34 (2008).
93. Villeneuve JP, Durantel D, Durantel S et al.: Selection of a hepatitis B virus strain resistant ot adefovir in a liver transplantation patient. J. Hepatol. 39, 1085-1089 (2003).
94. Locarnini S, Qi X, Arterburn S et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. 42(Suppl. 2), 17 (2005).
95. Villet S, Pichoud C, Billioud G et al.: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 48, 747-755 (2008).
96. Fung SK, Andreone P, Han SH et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43, 937-943 (2005).
97. Brunelle MN, Jacquard AC, Pichoud C et al.: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41, 1391-1398 (2005).
98. Schildgen O, Sirma H, Funk A et al.: Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 354, 1807-1812 (2006).
99. Kim DY, Lee JH, Lee DH et al.: Occurrence of primary adefovir resistance mutation in hepatitis B patients with YMDD mutation and lamivudine resistance. Gastroenterology 130(Suppl. 2), A-846 T1843 (2006).
100. Gane E, Lai C-L, Min A et al.: Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. J. Hepatol. 46(Suppl. 1), S187-S188 (2007).